Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Dispatch

Prevalence of SARS-CoV-2, Verona, Italy, April–May 2020

Massimo Guerriero1, Zeno Bisoffi1Comments to Author , Albino Poli, Claudio Micheletto, Antonio Conti, and Carlo Pomari
Author affiliations: Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Sacro Cuore Don Calabria, Negrar, Italy (M. Guerriero, Z. Bisoffi, A. Conti, C. Pomari); Università di Verona, Verona, Italy (Z. Bisoffi, A. Poli); Azienda Ospedaliera Universitaria di Verona, Verona (C. Micheletto)

Main Article

Table 2

Latent class analysis of SARS-CoV-2 infection, Verona, Italy, 2020

Factor Probability % (95% CI)
% (95% CI)
Class 1 (SARS-CoV-2–negative) Class 2 (SARS-CoV-2–positive) Sensitivity Specificity Positive predictive value Negative predictive value
SARS-CoV-2 IgG 1.1 (0.6–2.0) 53.5 (30.8–74.8) 53.5 (51.0–53.0) 98.9 (98.4–99.4) 60.1 (57.6–62.5) 98.6 (98.0–99.2)
SARS-CoV-2 RNA 0.5 (0.2–1.1) 6.1 (1.6–20.9) 6.1 (4.9–5.7) 99.5 (99.1–99.9) 27.4 (25.1–29.6) 97.2 (96.3–98.0)
Anosmia* 0.8 (0.03–1.8) 54.5 (33.2–74.2) 54.5 (52.0–54.1) 99.2 (98.8–99.6) 67.8 (65.5–70.2) 98.6 (98.0–99.2)
Diarrhea* 7.0 (5.7–8.6) 37.2 (21.6–55.9) 37.2 (34.8–35.9) 93.0 (91.7–94.3) 14.1 (12.4–15.9) 98.0 (97.2–98.7)
Fever* 1.3 (0.8–2.2) 45.8 (26.3–66.7) 45.8 (43.3–45.2) 98.7 (98.1–99.3) 52.1 (49.6–54.7) 98.3 (97.7–99.0)
Dyspnea* 2.6 (1.8–3.6) 32.3 (17.9−51.0) 32.3 (29.9–31.5) 97.4 (96.6–98.2) 27.8 (25.5–30.0) 97.9 (97.2–98.6)

*The clinical variables used in the latent class analysis were selected by backward stepwise multinomial logistic regression with a significance level for removal of 0.2.

Main Article

1These authors contributed equally to this article.

Page created: October 05, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external